Frazier Life Sciences Management, L.P. Arcutis Biotherapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q2 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 9,874,511 shares of ARQT stock, worth $246 Million. This represents 7.3% of its overall portfolio holdings.
Number of Shares
9,874,511
Previous 8,785,284
12.4%
Holding current value
$246 Million
Previous $137 Million
0.76%
% of portfolio
7.3%
Previous 8.65%
Shares
5 transactions
Others Institutions Holding ARQT
# of Institutions
247Shares Held
132MCall Options Held
407KPut Options Held
216K-
Jennison Associates LLC12.3MShares$305 Million0.14% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.5MShares$287 Million5.56% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$268 Million3.47% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$215 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.05MShares$176 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...